ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Targeted Restoration of the Microbial Tryptophan Oxidative Pathway Ameliorates Autism-Like Behavioral and Synaptic Deficits.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Autism Spectrum Disorder (ASD) is associated with gut microbiota dysbiosis, yet the contribution of specific microbial metabolic pathways remains unclear. Reanalysis of a public ASD cohort revealed reduced functional potential in microbial tryptophan oxidative metabolism. We therefore designed targeted microbial tryptophan oxidative pathway (MTOP) interventions comprising Lacticaseibacillus rhamnosus C502, highland barley β-glucan, or their synbiotic combination. These interventions enhanced oxidative tryptophan metabolic output and restored associated indole derivatives in ASD fecal cultures. In a VPA-induced autism-like mouse model, MTOP-targeted interventions alleviated behavioral deficits, normalized social-stimulus-associated CA3 calcium responses, and improved hippocampal synaptic architecture. These effects were accompanied by gut microbiota remodeling, improved intestinal barrier integrity, increased fecal and brain IAA levels, and restoration of ERK-CREB-BDNF-associated signaling. Microbiota depletion abolished the synbiotic-mediated benefits, whereas oral IAA supplementation partially reproduced behavioral, neuronal, and selected synaptic improvements. Neuronal AhR knockdown in the retrosplenial cortex attenuated the synbiotic-mediated rescue, supporting a required role for neuronal AhR. Independent clinical metabolomic analysis supported an association between lower circulating IAA and ASD symptom severity. Collectively, these findings identify impaired MTOP-related metabolism as a gut-brain metabolic vulnerability and support MTOP restoration as a candidate synbiotic strategy for ASD-related conditions characterized by impaired microbial tryptophan oxidative metabolism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.